Etana to Produce Cancer Drug after Securing Funding from DEG
Biopharmaceutical startup PT Etana Biotechnologies Indonesia (Etana) raised undisclosed funding from DEG, Yunfeng Capital, HighLight Capital, and East Ventures.
Etana President Director Nathan Tritana said with this funding, Etana aims to offer high-quality, innovative, and affordable biopharmaceutical products to Indonesia and other Southeast Asian countries. Etana plans to utilize the funds to establish local biopharmaceutical production capabilities.
Wilson Cuaca, East Ventures' co-founder and managing partner, said the COVID-19 pandemic had exposed the weakness of Indonesia's healthcare system.
Hence, all stakeholders must devise innovative and rapid solutions to address this health crisis. "Etana's products, such as vaccines, have augmented the national healthcare system's strength and resilience," he said.